Monteiro Andre, Khan Slah, Waqas Muhammad, Dossani Rimal H, Ruggiero Nicco, Siddiqi Nehaal M, Baig Ammad A, Rai Hamid H, Cappuzzo Justin M, Levy Elad I, Siddiqui Adnan H
Neurosurgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA.
Neurosurgery, Gates Vascular Institute, Buffalo, New York, USA.
J Neurointerv Surg. 2022 Jun;14(6):564-567. doi: 10.1136/neurintsurg-2021-018017. Epub 2021 Nov 2.
Acute isolated posterior cerebral artery occlusions (aPCAOs) were excluded or under-represented in major randomized trials of mechanical thrombectomy (MT). The benefit of MT in comparison to intravenous tissue plasminogen activator (alteplase; IV-tPA) alone in these patients remains controversial and uncertain.
We performed a systematic search of PubMed, MEDLINE, and EMBASE databases for articles comparing MT with or without bridging IV-tPA and IV-tPA alone for aPCAO using keywords ('posterior cerebral artery', 'thrombolysis' and 'thrombectomy') with Boolean operators. Extracted data from patients reported in the studies were pooled into groups (MT vs IV-tPA alone) for comparison. Estimated rates for favorable outcome (modified Rankin scale score 0-2), symptomatic intracranial hemorrhage (sICH), and mortality were extracted.
Seven articles (201 MT patients, 64 IV-tPA) were included, all retrospective. There was no statistically significant difference between pooled groups in median age, median presentation National Institutes of Health Stroke Scale (NIHSS) score, PCAO segment, and median time from symptom onset to puncture or needle. The recanalization rate was significantly higher in the MT group than the IV-tPA group (85.6% vs 53.1%, p<0.00001). Odds ratios for favorable outcome (OR 1.5, 95% CI 0.8 to 2.5), sICH (OR 1.1, 95% CI 0.2 to 5.5), and mortality (OR 1.4, 95% CI 0.5 to 3.6) did not significantly favor any modality.
We found no significant differences in odds of favorable outcome, sICH, and mortality in MT and IV-tPA in comparable aPCAO patients, despite superior MT recanalization rates. Equipoise remains regarding the optimal treatment modality for these patients.
急性孤立性大脑后动脉闭塞(aPCAO)在机械取栓(MT)的主要随机试验中被排除或代表性不足。在这些患者中,与单独静脉注射组织纤溶酶原激活剂(阿替普酶;静脉注射tPA)相比,MT的益处仍存在争议且不确定。
我们使用布尔运算符,通过关键词(“大脑后动脉”、“溶栓”和“取栓”)对PubMed、MEDLINE和EMBASE数据库进行系统检索,以查找比较MT联合或不联合桥接静脉注射tPA与单独静脉注射tPA治疗aPCAO的文章。将研究中报告的患者提取的数据汇总为组(MT与单独静脉注射tPA)进行比较。提取有利结局(改良Rankin量表评分0 - 2)、症状性颅内出血(sICH)和死亡率的估计率。
纳入7篇文章(201例MT患者,64例静脉注射tPA患者),均为回顾性研究。在合并组之间,中位年龄、中位就诊时美国国立卫生研究院卒中量表(NIHSS)评分、PCAO节段以及从症状发作到穿刺或注射的中位时间方面,差异均无统计学意义。MT组的再通率显著高于静脉注射tPA组(85.6%对53.1%,p<0.00001)。有利结局的优势比(OR 1.5,95%CI 0.8至2.5)、sICH(OR 1.1,95%CI 0.2至5.5)和死亡率(OR 1.4,95%CI 0.5至3.6)均未显著支持任何一种治疗方式。
我们发现,在具有可比性的aPCAO患者中,尽管MT的再通率更高,但MT和静脉注射tPA在有利结局、sICH和死亡率的几率方面并无显著差异。对于这些患者的最佳治疗方式仍存在 equipoise。 (注:equipoise 这个词在医学语境中较难准确翻译,可结合上下文理解为“平衡、权衡”等意思,这里保留英文以便读者理解其确切含义)